Nuvamid
A clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases
4 employees · est. 2019 · Nyon, Switzerland
Catalyst Biosciences is the older company (1997 vs 2019); Catalyst Biosciences is the larger of the two.
Side-by-Side Comparison
| Metric | Catalyst Biosciences | Nuvamid |
|---|---|---|
| Founded | ||
| Founded | 1997 older | 2019 |
| Headquarters | ||
| Headquarters | South San Francisco, United States | Nyon, Switzerland |
| Employees | ||
| Employees | 12 larger | 4 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Life Sciences | Health Care, Manufacturing, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Not tracked yet |
| Total Funding | ||
| Total Funding | $301.31M | Not tracked yet |
| Funding Rounds | ||
| Funding Rounds | 14 | Not tracked yet |
| Services | ||
| Services | Not tracked yet | Research and development of nucleotide-based therapies, Clinical stage trials for rare blood diseases, Collaboration with academic and research institutions |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with rare blood diseases, Healthcare providers specializing in rare diseases, Pharmaceutical and biotech partners |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical, Rare Disorders, Complement System, Coagulation System, Protease Engineering, Clinical Development, Hemophilia, Gene Therapy, Factor IX, Macular Degeneration, Recombinant Coagulation Factors, Complement Inhibitors, Intravitreal Therapeutics | Clinical Stage Biotech, Nucleotide Therapeutics, Rare Diseases, Endogenous Molecules, Breakthrough Therapeutics, Rare Blood Diseases, Blood Cell Disorders, NUV01, Phase 2 Clinical Trials, NAD Metabolism, NAD Metabolism Modulators, Preclinical Data, Immune Disorders, Research Collaborations, Biopharmaceutical Development |
| Website | ||
| Website | catalystbiosciences.com | nuvamid.com |
About Catalyst Biosciences
Catalyst Biosciences is an innovative biopharmaceutical company founded in 1997, focused on rare disorders of the complement and coagulation systems within the Health Care industry. Their protease engineering platform has yielded significant results, leading to the development of several promising p...
About Nuvamid
Nuvamid, founded in 2019 and headquartered in Switzerland, is a clinical stage biotech with a focus on the research and utilization of nucleotides as therapeutics for rare diseases. Known for their slogan, "A clinical stage biotech focused on the research and use of nucleotides, as therapeutics for...
We will tell you when either one moves
BounceWatch watches Catalyst Biosciences and Nuvamid for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Catalyst Biosciences and Nuvamid — by email.
Frequently Asked Questions
Compare Catalyst Biosciences with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Catalyst Biosciences on 12 Sep 2024, and Nuvamid on 4 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
